Table of Content

1 Cancer Immunotherapy Drug Market Overview
1.1 Product Overview and Scope of Cancer Immunotherapy Drug
1.2 Cancer Immunotherapy Drug Segment by Type
1.2.1 Global Cancer Immunotherapy Drug Market Value Comparison by Type (2024-2034)
1.2.2 PD-1 Inhibitor
1.2.3 PDL-1 Inhibitor
1.2.4 T-Cell Stimulant
1.2.5 CTLA Antibody
1.3 Cancer Immunotherapy Drug Segment by Application
1.3.1 Global Cancer Immunotherapy Drug Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Cancer Immunotherapy Drug Market Size Estimates and Forecasts
1.4.1 Global Cancer Immunotherapy Drug Revenue 2024-2034
1.4.2 Global Cancer Immunotherapy Drug Sales 2024-2034
1.4.3 Global Cancer Immunotherapy Drug Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Cancer Immunotherapy Drug Market Competition by Manufacturers
2.1 Global Cancer Immunotherapy Drug Sales Market Share by Manufacturers (2024-2024)
2.2 Global Cancer Immunotherapy Drug Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Cancer Immunotherapy Drug Average Price by Manufacturers (2024-2024)
2.4 Global Cancer Immunotherapy Drug Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Cancer Immunotherapy Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Immunotherapy Drug, Product Type & Application
2.7 Cancer Immunotherapy Drug Market Competitive Situation and Trends
2.7.1 Cancer Immunotherapy Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cancer Immunotherapy Drug Players Market Share by Revenue
2.7.3 Global Cancer Immunotherapy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cancer Immunotherapy Drug Retrospective Market Scenario by Region
3.1 Global Cancer Immunotherapy Drug Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Cancer Immunotherapy Drug Global Cancer Immunotherapy Drug Sales by Region: 2024-2034
3.2.1 Global Cancer Immunotherapy Drug Sales by Region: 2024-2024
3.2.2 Global Cancer Immunotherapy Drug Sales by Region: 2024-2034
3.3 Global Cancer Immunotherapy Drug Global Cancer Immunotherapy Drug Revenue by Region: 2024-2034
3.3.1 Global Cancer Immunotherapy Drug Revenue by Region: 2024-2024
3.3.2 Global Cancer Immunotherapy Drug Revenue by Region: 2024-2034
3.4 North America Cancer Immunotherapy Drug Market Facts & Figures by Country
3.4.1 North America Cancer Immunotherapy Drug Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Cancer Immunotherapy Drug Sales by Country (2024-2034)
3.4.3 North America Cancer Immunotherapy Drug Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cancer Immunotherapy Drug Market Facts & Figures by Country
3.5.1 Europe Cancer Immunotherapy Drug Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Cancer Immunotherapy Drug Sales by Country (2024-2034)
3.5.3 Europe Cancer Immunotherapy Drug Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Immunotherapy Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Cancer Immunotherapy Drug Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Cancer Immunotherapy Drug Sales by Country (2024-2034)
3.6.3 Asia Pacific Cancer Immunotherapy Drug Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Cancer Immunotherapy Drug Market Facts & Figures by Country
3.7.1 Latin America Cancer Immunotherapy Drug Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Cancer Immunotherapy Drug Sales by Country (2024-2034)
3.7.3 Latin America Cancer Immunotherapy Drug Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Immunotherapy Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Immunotherapy Drug Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2024-2034)
3.8.3 Middle East and Africa Cancer Immunotherapy Drug Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cancer Immunotherapy Drug Sales by Type (2024-2034)
4.1.1 Global Cancer Immunotherapy Drug Sales by Type (2024-2024)
4.1.2 Global Cancer Immunotherapy Drug Sales by Type (2024-2034)
4.1.3 Global Cancer Immunotherapy Drug Sales Market Share by Type (2024-2034)
4.2 Global Cancer Immunotherapy Drug Revenue by Type (2024-2034)
4.2.1 Global Cancer Immunotherapy Drug Revenue by Type (2024-2024)
4.2.2 Global Cancer Immunotherapy Drug Revenue by Type (2024-2034)
4.2.3 Global Cancer Immunotherapy Drug Revenue Market Share by Type (2024-2034)
4.3 Global Cancer Immunotherapy Drug Price by Type (2024-2034)
5 Segment by Application
5.1 Global Cancer Immunotherapy Drug Sales by Application (2024-2034)
5.1.1 Global Cancer Immunotherapy Drug Sales by Application (2024-2024)
5.1.2 Global Cancer Immunotherapy Drug Sales by Application (2024-2034)
5.1.3 Global Cancer Immunotherapy Drug Sales Market Share by Application (2024-2034)
5.2 Global Cancer Immunotherapy Drug Revenue by Application (2024-2034)
5.2.1 Global Cancer Immunotherapy Drug Revenue by Application (2024-2024)
5.2.2 Global Cancer Immunotherapy Drug Revenue by Application (2024-2034)
5.2.3 Global Cancer Immunotherapy Drug Revenue Market Share by Application (2024-2034)
5.3 Global Cancer Immunotherapy Drug Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Autolus Therapeutics plc
6.1.1 Autolus Therapeutics plc Corporation Information
6.1.2 Autolus Therapeutics plc Description and Business Overview
6.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio
6.1.5 Autolus Therapeutics plc Recent Developments/Updates
6.2 BeiGene
6.2.1 BeiGene Corporation Information
6.2.2 BeiGene Description and Business Overview
6.2.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.2.4 BeiGene Cancer Immunotherapy Drug Product Portfolio
6.2.5 BeiGene Recent Developments/Updates
6.3 bluebird bio, Inc.
6.3.1 bluebird bio, Inc. Corporation Information
6.3.2 bluebird bio, Inc. Description and Business Overview
6.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio
6.3.5 bluebird bio, Inc. Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Corporation Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Celgene Corporation
6.5.1 Celgene Corporation Corporation Information
6.5.2 Celgene Corporation Description and Business Overview
6.5.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Celgene Corporation Cancer Immunotherapy Drug Product Portfolio
6.5.5 Celgene Corporation Recent Developments/Updates
6.6 AstraZeneca plc
6.6.1 AstraZeneca plc Corporation Information
6.6.2 AstraZeneca plc Description and Business Overview
6.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio
6.6.5 AstraZeneca plc Recent Developments/Updates
6.7 Gilead Sciences, Inc.
6.6.1 Gilead Sciences, Inc. Corporation Information
6.6.2 Gilead Sciences, Inc. Description and Business Overview
6.6.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Portfolio
6.7.5 Gilead Sciences, Inc. Recent Developments/Updates
6.8 Incyte Corporation
6.8.1 Incyte Corporation Corporation Information
6.8.2 Incyte Corporation Description and Business Overview
6.8.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Incyte Corporation Cancer Immunotherapy Drug Product Portfolio
6.8.5 Incyte Corporation Recent Developments/Updates
6.9 Jiangsu Hengrui Medicine
6.9.1 Jiangsu Hengrui Medicine Corporation Information
6.9.2 Jiangsu Hengrui Medicine Description and Business Overview
6.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Portfolio
6.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
6.10 Juno Pharmaceuticals Pty Ltd.
6.10.1 Juno Pharmaceuticals Pty Ltd. Corporation Information
6.10.2 Juno Pharmaceuticals Pty Ltd. Description and Business Overview
6.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio
6.10.5 Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
6.11 Medimmune, LLC
6.11.1 Medimmune, LLC Corporation Information
6.11.2 Medimmune, LLC Cancer Immunotherapy Drug Description and Business Overview
6.11.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio
6.11.5 Medimmune, LLC Recent Developments/Updates
6.12 Merck & Co., Inc.
6.12.1 Merck & Co., Inc. Corporation Information
6.12.2 Merck & Co., Inc. Cancer Immunotherapy Drug Description and Business Overview
6.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio
6.12.5 Merck & Co., Inc. Recent Developments/Updates
6.13 Novartis AG
6.13.1 Novartis AG Corporation Information
6.13.2 Novartis AG Cancer Immunotherapy Drug Description and Business Overview
6.13.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Novartis AG Cancer Immunotherapy Drug Product Portfolio
6.13.5 Novartis AG Recent Developments/Updates
6.14 Pfizer, Inc.
6.14.1 Pfizer, Inc. Corporation Information
6.14.2 Pfizer, Inc. Cancer Immunotherapy Drug Description and Business Overview
6.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio
6.14.5 Pfizer, Inc. Recent Developments/Updates
6.15 Roche Holding AG
6.15.1 Roche Holding AG Corporation Information
6.15.2 Roche Holding AG Cancer Immunotherapy Drug Description and Business Overview
6.15.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2024-2024)
6.15.4 Roche Holding AG Cancer Immunotherapy Drug Product Portfolio
6.15.5 Roche Holding AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Immunotherapy Drug Industry Chain Analysis
7.2 Cancer Immunotherapy Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Immunotherapy Drug Production Mode & Process
7.4 Cancer Immunotherapy Drug Sales and Marketing
7.4.1 Cancer Immunotherapy Drug Sales Channels
7.4.2 Cancer Immunotherapy Drug Distributors
7.5 Cancer Immunotherapy Drug Customers
8 Cancer Immunotherapy Drug Market Dynamics
8.1 Cancer Immunotherapy Drug Industry Trends
8.2 Cancer Immunotherapy Drug Market Drivers
8.3 Cancer Immunotherapy Drug Market Challenges
8.4 Cancer Immunotherapy Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Cancer Immunotherapy Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Cancer Immunotherapy Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Cancer Immunotherapy Drug Market Competitive Situation by Manufacturers in 2022
Table 4. Global Cancer Immunotherapy Drug Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Cancer Immunotherapy Drug Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Cancer Immunotherapy Drug Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Cancer Immunotherapy Drug Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Cancer Immunotherapy Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Cancer Immunotherapy Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cancer Immunotherapy Drug, Product Type & Application
Table 12. Global Key Manufacturers of Cancer Immunotherapy Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cancer Immunotherapy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drug as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cancer Immunotherapy Drug Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Cancer Immunotherapy Drug Sales by Region (2024-2024) & (K Units)
Table 18. Global Cancer Immunotherapy Drug Sales Market Share by Region (2024-2024)
Table 19. Global Cancer Immunotherapy Drug Sales by Region (2024-2034) & (K Units)
Table 20. Global Cancer Immunotherapy Drug Sales Market Share by Region (2024-2034)
Table 21. Global Cancer Immunotherapy Drug Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2024-2024)
Table 23. Global Cancer Immunotherapy Drug Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2024-2034)
Table 25. North America Cancer Immunotherapy Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Cancer Immunotherapy Drug Sales by Country (2024-2024) & (K Units)
Table 27. North America Cancer Immunotherapy Drug Sales by Country (2024-2034) & (K Units)
Table 28. North America Cancer Immunotherapy Drug Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Cancer Immunotherapy Drug Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Cancer Immunotherapy Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Cancer Immunotherapy Drug Sales by Country (2024-2024) & (K Units)
Table 32. Europe Cancer Immunotherapy Drug Sales by Country (2024-2034) & (K Units)
Table 33. Europe Cancer Immunotherapy Drug Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Cancer Immunotherapy Drug Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Cancer Immunotherapy Drug Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Cancer Immunotherapy Drug Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Cancer Immunotherapy Drug Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Cancer Immunotherapy Drug Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Cancer Immunotherapy Drug Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Cancer Immunotherapy Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Cancer Immunotherapy Drug Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Cancer Immunotherapy Drug Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Cancer Immunotherapy Drug Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Cancer Immunotherapy Drug Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Cancer Immunotherapy Drug Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Cancer Immunotherapy Drug Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Cancer Immunotherapy Drug Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Cancer Immunotherapy Drug Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Cancer Immunotherapy Drug Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Cancer Immunotherapy Drug Sales (K Units) by Type (2024-2024)
Table 51. Global Cancer Immunotherapy Drug Sales (K Units) by Type (2024-2034)
Table 52. Global Cancer Immunotherapy Drug Sales Market Share by Type (2024-2024)
Table 53. Global Cancer Immunotherapy Drug Sales Market Share by Type (2024-2034)
Table 54. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2024-2024)
Table 57. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2024-2034)
Table 58. Global Cancer Immunotherapy Drug Price (US$/Unit) by Type (2024-2024)
Table 59. Global Cancer Immunotherapy Drug Price (US$/Unit) by Type (2024-2034)
Table 60. Global Cancer Immunotherapy Drug Sales (K Units) by Application (2024-2024)
Table 61. Global Cancer Immunotherapy Drug Sales (K Units) by Application (2024-2034)
Table 62. Global Cancer Immunotherapy Drug Sales Market Share by Application (2024-2024)
Table 63. Global Cancer Immunotherapy Drug Sales Market Share by Application (2024-2034)
Table 64. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2024-2024)
Table 67. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2024-2034)
Table 68. Global Cancer Immunotherapy Drug Price (US$/Unit) by Application (2024-2024)
Table 69. Global Cancer Immunotherapy Drug Price (US$/Unit) by Application (2024-2034)
Table 70. Autolus Therapeutics plc Corporation Information
Table 71. Autolus Therapeutics plc Description and Business Overview
Table 72. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. Autolus Therapeutics plc Cancer Immunotherapy Drug Product
Table 74. Autolus Therapeutics plc Recent Developments/Updates
Table 75. BeiGene Corporation Information
Table 76. BeiGene Description and Business Overview
Table 77. BeiGene Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. BeiGene Cancer Immunotherapy Drug Product
Table 79. BeiGene Recent Developments/Updates
Table 80. bluebird bio, Inc. Corporation Information
Table 81. bluebird bio, Inc. Description and Business Overview
Table 82. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. bluebird bio, Inc. Cancer Immunotherapy Drug Product
Table 84. bluebird bio, Inc. Recent Developments/Updates
Table 85. Bristol-Myers Squibb Corporation Information
Table 86. Bristol-Myers Squibb Description and Business Overview
Table 87. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Bristol-Myers Squibb Cancer Immunotherapy Drug Product
Table 89. Bristol-Myers Squibb Recent Developments/Updates
Table 90. Celgene Corporation Corporation Information
Table 91. Celgene Corporation Description and Business Overview
Table 92. Celgene Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Celgene Corporation Cancer Immunotherapy Drug Product
Table 94. Celgene Corporation Recent Developments/Updates
Table 95. AstraZeneca plc Corporation Information
Table 96. AstraZeneca plc Description and Business Overview
Table 97. AstraZeneca plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. AstraZeneca plc Cancer Immunotherapy Drug Product
Table 99. AstraZeneca plc Recent Developments/Updates
Table 100. Gilead Sciences, Inc. Corporation Information
Table 101. Gilead Sciences, Inc. Description and Business Overview
Table 102. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product
Table 104. Gilead Sciences, Inc. Recent Developments/Updates
Table 105. Incyte Corporation Corporation Information
Table 106. Incyte Corporation Description and Business Overview
Table 107. Incyte Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Incyte Corporation Cancer Immunotherapy Drug Product
Table 109. Incyte Corporation Recent Developments/Updates
Table 110. Jiangsu Hengrui Medicine Corporation Information
Table 111. Jiangsu Hengrui Medicine Description and Business Overview
Table 112. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product
Table 114. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 115. Juno Pharmaceuticals Pty Ltd. Corporation Information
Table 116. Juno Pharmaceuticals Pty Ltd. Description and Business Overview
Table 117. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product
Table 119. Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
Table 120. Medimmune, LLC Corporation Information
Table 121. Medimmune, LLC Description and Business Overview
Table 122. Medimmune, LLC Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. Medimmune, LLC Cancer Immunotherapy Drug Product
Table 124. Medimmune, LLC Recent Developments/Updates
Table 125. Merck & Co., Inc. Corporation Information
Table 126. Merck & Co., Inc. Description and Business Overview
Table 127. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. Merck & Co., Inc. Cancer Immunotherapy Drug Product
Table 129. Merck & Co., Inc. Recent Developments/Updates
Table 130. Novartis AG Corporation Information
Table 131. Novartis AG Description and Business Overview
Table 132. Novartis AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Novartis AG Cancer Immunotherapy Drug Product
Table 134. Novartis AG Recent Developments/Updates
Table 135. Pfizer, Inc. Corporation Information
Table 136. Pfizer, Inc. Description and Business Overview
Table 137. Pfizer, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Pfizer, Inc. Cancer Immunotherapy Drug Product
Table 139. Pfizer, Inc. Recent Developments/Updates
Table 140. Roche Holding AG Corporation Information
Table 141. Roche Holding AG Description and Business Overview
Table 142. Roche Holding AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 143. Roche Holding AG Cancer Immunotherapy Drug Product
Table 144. Roche Holding AG Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Cancer Immunotherapy Drug Distributors List
Table 148. Cancer Immunotherapy Drug Customers List
Table 149. Cancer Immunotherapy Drug Market Trends
Table 150. Cancer Immunotherapy Drug Market Drivers
Table 151. Cancer Immunotherapy Drug Market Challenges
Table 152. Cancer Immunotherapy Drug Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cancer Immunotherapy Drug
Figure 2. Global Cancer Immunotherapy Drug Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Cancer Immunotherapy Drug Market Share by Type in 2022 & 2034
Figure 4. PD-1 Inhibitor Product Picture
Figure 5. PDL-1 Inhibitor Product Picture
Figure 6. T-Cell Stimulant Product Picture
Figure 7. CTLA Antibody Product Picture
Figure 8. Global Cancer Immunotherapy Drug Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Cancer Immunotherapy Drug Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Cancer Immunotherapy Drug Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 14. Global Cancer Immunotherapy Drug Market Size (2024-2034) & (US$ Million)
Figure 15. Global Cancer Immunotherapy Drug Sales (2024-2034) & (K Units)
Figure 16. Global Cancer Immunotherapy Drug Average Price (US$/Unit) & (2024-2034)
Figure 17. Cancer Immunotherapy Drug Report Years Considered
Figure 18. Cancer Immunotherapy Drug Sales Share by Manufacturers in 2022
Figure 19. Global Cancer Immunotherapy Drug Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest Cancer Immunotherapy Drug Players: Market Share by Revenue in 2022
Figure 21. Cancer Immunotherapy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 22. Global Cancer Immunotherapy Drug Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 23. North America Cancer Immunotherapy Drug Sales Market Share by Country (2024-2034)
Figure 24. North America Cancer Immunotherapy Drug Revenue Market Share by Country (2024-2034)
Figure 25. United States Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 26. Canada Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. Europe Cancer Immunotherapy Drug Sales Market Share by Country (2024-2034)
Figure 28. Europe Cancer Immunotherapy Drug Revenue Market Share by Country (2024-2034)
Figure 29. Germany Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. France Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. U.K. Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Italy Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. Russia Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Asia Pacific Cancer Immunotherapy Drug Sales Market Share by Region (2024-2034)
Figure 35. Asia Pacific Cancer Immunotherapy Drug Revenue Market Share by Region (2024-2034)
Figure 36. China Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Japan Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. South Korea Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. India Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Australia Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. China Taiwan Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Southeast Asia Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Latin America Cancer Immunotherapy Drug Sales Market Share by Country (2024-2034)
Figure 44. Latin America Cancer Immunotherapy Drug Revenue Market Share by Country (2024-2034)
Figure 45. Mexico Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Brazil Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 47. Argentina Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Middle East & Africa Cancer Immunotherapy Drug Sales Market Share by Country (2024-2034)
Figure 49. Middle East & Africa Cancer Immunotherapy Drug Revenue Market Share by Country (2024-2034)
Figure 50. Turkey Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. Saudi Arabia Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 52. UAE Cancer Immunotherapy Drug Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 53. Global Sales Market Share of Cancer Immunotherapy Drug by Type (2024-2034)
Figure 54. Global Revenue Market Share of Cancer Immunotherapy Drug by Type (2024-2034)
Figure 55. Global Cancer Immunotherapy Drug Price (US$/Unit) by Type (2024-2034)
Figure 56. Global Sales Market Share of Cancer Immunotherapy Drug by Application (2024-2034)
Figure 57. Global Revenue Market Share of Cancer Immunotherapy Drug by Application (2024-2034)
Figure 58. Global Cancer Immunotherapy Drug Price (US$/Unit) by Application (2024-2034)
Figure 59. Cancer Immunotherapy Drug Value Chain
Figure 60. Cancer Immunotherapy Drug Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed